Abstract

This is a preliminary study utilizing drug targeting approach for developing sildenafil citrate (SFC) pulmonary delivery system, a first #x2013; line for pulmonary arterial hypertension (PAH) treatment and hence reducing the dose and the side effects. The closed melt method was employed for preparing SFC #x2013; solid lipid microparticles dispersions (SFC #x2013; SLMDs), a non #x2013; solvent technique aid in the production of drug #x2013; matrix dispersions with sustained release properties. Glyceryl behenate (GB) (Compritol#xAE; 888 ATO) was used as the retarding matrix and the results shown that as its ratio increase there was a decrease in the fine particle fraction, an increase in the drug content and a prolong drug release pattern. The best model fit the release data was Higuchi #x2013; Matrix model which indicates drug diffusion #x2013; controlled releasing mechanism. Thus, inhaled SFC #x2013; SLMDs dry powder will improve PAH treatment via drug localization at low doses and reducing the administration frequency.